FDA grants plinabulin Fast Track as BeyondSpring reports $0.6m cash balance
The regulatory boost for the lung cancer combination arrives as the company's quarter-end cash and ongoing hunt for funding cloud how it will finance late-stage work.
BeyondSpring has secured a regulatory advantage for its lead programme but ended the third quarter with only $0.6m in cash. The US Food and Drug Administration has given Fast Track designation to plinabulin used with docetaxel, the company said on 13 November 2026 as it published quarterly results.
The designation applies to adults with advanced or metastatic non-squamous non-small cell lung cancer who have no actionable genomic alterations and whose disease has progressed following anti-PD-(L)1 treatment and platinum-based chemotherapy. The company reported a net loss of $2.1m for the quarter and said it is still seeking financing.
By way of context, Fast Track is an FDA scheme meant to accelerate development and review of treatments for serious conditions with unmet need. It can allow more frequent contact with the agency and, if eligibility criteria are met, rolling submission of an application. It is not an approval and does not guarantee a quicker outcome.
BeyondSpring also said it completed the sale of its Bulin-holding subsidiary to Biolin on 30 September. As part of the arrangement, Biolin is paying for about half of enrolment in DUBLIN-4, a planned Phase 3 study of 442 patients, with that share of recruitment taking place in China. The facts provided do not say how the remainder of the trial will be paid for, or give the financial terms of the sale.
Why it matters
- Fast Track may open up closer dialogue with the FDA on the plinabulin-docetaxel plan, but it carries no implication of approval or faster review.
- The target group, non-squamous NSCLC after anti-PD-(L)1 and platinum therapy without actionable alterations, is one where docetaxel serves as a relevant comparator for regulators and payers.
- Biolin's funding of roughly half of DUBLIN-4 enrolment in China eases part of the trial burden, yet the $0.6m cash balance leaves open how the rest will be financed.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
Lifeward Q3 revenue falls 12% as AlterG grows and ReWalk moves to channel partners
